{
    "id": 2936,
    "fullName": "SRC over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SRC over exp indicates an over expression of the Src protein. However, the mechanism causing the over expression is not specified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6714,
        "geneSymbol": "SRC",
        "terms": [
            "SRC",
            "ASV",
            "c-SRC",
            "p60-Src",
            "SRC1",
            "THC6"
        ]
    },
    "variant": "over exp",
    "createDate": "01/14/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5936,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, baseline expression of SRC was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).",
            "molecularProfile": {
                "id": 2760,
                "profileName": "SRC over exp"
            },
            "therapy": {
                "id": 3922,
                "therapyName": "Cediranib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5202,
                    "pubMedId": 26802156,
                    "title": "A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26802156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7456,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).",
            "molecularProfile": {
                "id": 25513,
                "profileName": "ERBB2 over exp PIK3CA H1047R SRC over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6363,
                    "pubMedId": 26270481,
                    "title": "Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26270481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7457,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).",
            "molecularProfile": {
                "id": 25513,
                "profileName": "ERBB2 over exp PIK3CA H1047R SRC over exp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6363,
                    "pubMedId": 26270481,
                    "title": "Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26270481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2760,
            "profileName": "SRC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2761,
            "profileName": "ALK fusion SRC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25513,
            "profileName": "ERBB2 over exp PIK3CA H1047R SRC over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}